Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 301

1.

Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.

Iijima M, Banno K, Okawa R, Yanokura M, Iida M, Takeda T, Kunitomi-Irie H, Adachi M, Nakamura K, Umene K, Nogami Y, Masuda K, Tominaga E, Aoki D.

Oncol Lett. 2017 Mar;13(3):1063-1070. doi: 10.3892/ol.2017.5582. Epub 2017 Jan 10.

2.

Genomic and proteomic characterization of ARID1A chromatin remodeller in ampullary tumors.

Nastase A, Teo JY, Heng HL, Ng CC, Myint SS, Rajasegaran V, Loh JL, Lee SY, Ooi LL, Chung AY, Chow PK, Cheow PC, Wan WK, Azhar R, Khoo A, Xiu SX, Alkaff SM, Cutcutache I, Lim JQ, Ong CK, Herlea V, Dima S, Duda DG, Teh BT, Popescu I, Lim TK.

Am J Cancer Res. 2017 Mar 1;7(3):484-502. eCollection 2017.

3.

Malignant extracellular vesicles carrying MMP1 mRNA facilitate peritoneal dissemination in ovarian cancer.

Yokoi A, Yoshioka Y, Yamamoto Y, Ishikawa M, Ikeda SI, Kato T, Kiyono T, Takeshita F, Kajiyama H, Kikkawa F, Ochiya T.

Nat Commun. 2017 Mar 6;8:14470. doi: 10.1038/ncomms14470.

4.

Downregulation of ARID1A, a component of the SWI/SNF chromatin remodeling complex, in breast cancer.

Takao C, Morikawa A, Ohkubo H, Kito Y, Saigo C, Sakuratani T, Futamura M, Takeuchi T, Yoshida K.

J Cancer. 2017 Jan 1;8(1):1-8. doi: 10.7150/jca.16602. eCollection 2017.

5.

Individual Bromodomains of Polybromo-1 Contribute to Chromatin Association and Tumor Suppression in Clear Cell Renal Carcinoma.

Porter EG, Dykhuizen EC.

J Biol Chem. 2017 Feb 17;292(7):2601-2610. doi: 10.1074/jbc.M116.746875. Epub 2017 Jan 4.

PMID:
28053089
6.

Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer.

Wilkerson PM, Dedes KJ, Samartzis EP, Dedes I, Lambros MB, Natrajan R, Gauthier A, Piscuoglio S, Töpfer C, Vukovic V, Daley F, Weigelt B, Reis-Filho JS.

Oncotarget. 2017 Jan 24;8(4):6057-6066. doi: 10.18632/oncotarget.14011.

7.

Improved clinical outcomes of patients with ovarian carcinoma arising in endometriosis.

Lu J, Tao X, Zhou J, Lu Y, Wang Z, Liu H, Xu C.

Oncotarget. 2017 Jan 24;8(4):5843-5852. doi: 10.18632/oncotarget.13967.

8.

Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment.

Rojas V, Hirshfield KM, Ganesan S, Rodriguez-Rodriguez L.

Int J Mol Sci. 2016 Dec 15;17(12). pii: E2113. Review.

9.

LncBRM initiates YAP1 signalling activation to drive self-renewal of liver cancer stem cells.

Zhu P, Wang Y, Wu J, Huang G, Liu B, Ye B, Du Y, Gao G, Tian Y, He L, Fan Z.

Nat Commun. 2016 Dec 1;7:13608. doi: 10.1038/ncomms13608.

10.

Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression.

Choi JY, Han HH, Kim YT, Lee JH, Kim BG, Kang S, Cho NH.

Yonsei Med J. 2017 Jan;58(1):59-66. doi: 10.3349/ymj.2017.58.1.59.

11.

Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer.

Alifrangis C, Thornton A, Fotopoulou C, Krell J, Gabra H.

Gynecol Oncol Rep. 2016 Nov 6;18:42-44. eCollection 2016 Nov.

12.

Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary.

Kato M, Takano M, Miyamoto M, Sasaki N, Goto T, Suzuki A, Hirata J, Sasa H, Tsuda H, Furuya K.

Mol Clin Oncol. 2016 Oct;5(4):395-401. Epub 2016 Aug 2.

13.

MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53.

Makii C, Oda K, Ikeda Y, Sone K, Hasegawa K, Uehara Y, Nishijima A, Asada K, Koso T, Fukuda T, Inaba K, Oki S, Machino H, Kojima M, Kashiyama T, Mori-Uchino M, Arimoto T, Wada-Hiraike O, Kawana K, Yano T, Fujiwara K, Aburatani H, Osuga Y, Fujii T.

Oncotarget. 2016 Nov 15;7(46):75328-75338. doi: 10.18632/oncotarget.12175.

14.

The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level.

Goldman AR, Bitler BG, Schug Z, Conejo-Garcia JR, Zhang R, Speicher DW.

Mol Cell Proteomics. 2016 Nov;15(11):3348-3360. Epub 2016 Sep 21.

15.

Integrative analysis of mutational and transcriptional profiles reveals driver mutations of metastatic breast cancers.

Lee JH, Zhao XM, Yoon I, Lee JY, Kwon NH, Wang YY, Lee KM, Lee MJ, Kim J, Moon HG, In Y, Hao JK, Park KM, Noh DY, Han W, Kim S.

Cell Discov. 2016 Aug 30;2:16025. doi: 10.1038/celldisc.2016.25. eCollection 2016.

16.

Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.

Lindqvist CM, Lundmark A, Nordlund J, Freyhult E, Ekman D, Carlsson Almlöf J, Raine A, Övernäs E, Abrahamsson J, Frost BM, Grandér D, Heyman M, Palle J, Forestier E, Lönnerholm G, Berglund EC, Syvänen AC.

Oncotarget. 2016 Sep 27;7(39):64071-64088. doi: 10.18632/oncotarget.11773.

17.

Clear cell ovarian cancer and endometriosis: is there a relationship?

Szubert M, Suzin J, Obirek K, Sochacka A, Łoszakiewicz M.

Prz Menopauzalny. 2016 Jun;15(2):85-9. doi: 10.5114/pm.2016.61190. Epub 2016 Jul 22.

18.

Arid1a controls tissue regeneration.

Wu S, Zhang R, Bitler BG.

Stem Cell Investig. 2016 Aug 9;3:35. doi: 10.21037/sci.2016.07.07. eCollection 2016. No abstract available.

19.

Enhancer deregulation in cancer and other diseases.

Herz HM.

Bioessays. 2016 Oct;38(10):1003-15. doi: 10.1002/bies.201600106. Epub 2016 Aug 29.

PMID:
27570183
20.

Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment.

Llorca-Cardeñosa MJ, Fleitas T, Ibarrola-Villava M, Peña-Chilet M, Mongort C, Martinez-Ciarpaglini C, Navarro L, Gambardella V, Castillo J, Roselló S, Navarro S, Ribas G, Cervantes A.

Oncotarget. 2016 Sep 27;7(39):63424-63436. doi: 10.18632/oncotarget.11520.

Supplemental Content

Support Center